New long-acting injection could give GSK an edge in the HIV market

Aug 15, 2018

Positive trial results have given GlaxoSmithKline’s HIV division hope that it could gain new ground in the market for HIV treatments. 

A new injection developed by the company has proven to be just as effective as the standard course of medications. One of the major benefits is that the treatment would decrease the dosing by patients from three pills a day to two injections a month.

Reducing toxicity and the amount of daily medications needed to treat HIV have been common concerns among patients.

The company said that it intends to release more details about the study later this year and file for regulatory approval. The market for HIV treatments in the U.S. is currently dominated by Gilead Sciences.

Read the full Financial Times report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments